The OlympiA trial demonstrated that early-stage, high-risk, HER2-, gBRCAm-positive breast cancer patients can benefit from the PARP inhibitor, olaparib, in the adjuvant setting. This evidence concerns the gene ERBB2 and breast carcinoma.